51473-23-5|Lergotrile mesylate|2-((6aR,9S,10aR)-5-chloro-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl)acetonitrile methanesulfonate|-范德生物科技公司

Lergotrile mesylate

NMR下载 COA and HPLC MSDS下载
names：
2-((6aR,9S,10aR)-5-chloro-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl)acetonitrile methanesulfonate
CAS号：
51473-23-5
MDL Number：
MF(分子式)： C18H22ClN3O3S MW(分子量)： 395.9
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Lergotrile mesylate
英文别名	Lergotrile mesylate; LY 83636; LY-83636; LY83636; 83636;
CAS号	51473-23-5
Inchi	InChI=1S/C17H18ClN3.CH4O3S/c1-21-9-10(5-6-19)7-12-11-3-2-4-14-16(11)13(8-15(12)21)17(18)20-14;1-5(2,3)4/h2-4,10,12,15,20H,5,7-9H2,1H3;1H3,(H,2,3,4)/t10-,12-,15-;/m1./s1
InchiKey	WXHDJVDIJQDJMK-AYJWUPBJSA-N
分子式 Formula	C18H22ClN3O3S
分子量 Molecular Weight	395.9
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Lergotrile mesylate(CAS:51473-23-5):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Lergotrile mesylate is an ergoline derivative that inhibits prolactin in vivo and in vitro.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Sherman BM, Swanson JA, Chapler FK. The treatment of hyperprolactinemia with a new ergot derivative, lergotrile mesylate. Fertil Steril. 1978 Mar;29(3):291-5. PubMed PMID: 565303.

[2]Clemens JA, Smalstig EB, Shaar CJ. Inhibition of prolactin secretion by lergotrile mesylate: mechanism of action. Acta Endocrinol (Copenh). 1975 Jun;79(2):230-7. PubMed PMID: 166535.

[3] Schmidt MJ. Dopamine agonist-induced hyperglycemia in rats: effects of lergotrile mesylate. Eur J Pharmacol. 1979 Oct 26;59(1-2):95-101. PubMed PMID: 41730.

[4] Lieberman A, Estey E, Kupersmith M, Gopinathan G, Goldstein M. Treatment of Parkinson's disease with lergotrile mesylate. JAMA. 1977 Nov 28;238(22):2380-2. PubMed PMID: 335094.

[5] Fuller RW, Perry KW. Effect of lergotrile on 3,4-dihydroxyphenylacetic acid (DOPAC) concentration and dopamine turnover in rat brain. J Neural Transm. 1978;42(1):23-35. PubMed PMID: 641542.

6: Thorner MO, Ryan SM, Wass JA, Jones A, Bouloux P, Williams S, Besser GM. Effect of the dopamine agonist, lergotrile mesylate, on circulating anterior pituitary hormones in man. J Clin Endocrinol Metab. 1978 Aug;47(2):372-8. PubMed PMID: 45463.7: Hooley RD, Fell LR, Findlay JK. The effect of 2-bromo-alpha-ergocryptine and 2-chloro-alpha-methylergoline-8beta-acetonitrile (lergotrile mesylate) on the prolactin secretion of the ewe. Acta Endocrinol (Copenh). 1977 Dec;86(4):722-7. PubMed PMID: 411304.8: Sinha YN, Salocks CB, VanderLaan WP. A comparison of the effects of CB-154 and lergotrile mesylate on prolactin and growth hormone secretion in mice. Horm Metab Res. 1976 Sep;8(5):332-6. PubMed PMID: 989755.9: Sved AF, Fernstrom JD. Reduction in blood pressure in normal and spontaneously hypertensive rats by lergotrile mesylate. J Pharm Pharmacol. 1979 Dec;31(12):814-7. PubMed PMID: 43364.10: Wiggins C, Wise PM, Ratner A. Differences in the response pattern of aged female rats to treatment with lergotrile mesylate. Proc Soc Exp Biol Med. 1985 Jun;179(2):173-9. PubMed PMID: 2859599.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开